Analysts at RBC Capital Kept their Past ‘Sector Perform’ rating on Shares Baxter International (NYSE:BAX), Set a $70 TP

November 9, 2018 - By Daniel Cummings

Baxter International Inc. (NYSE:BAX) Logo

Investors sentiment increased to 0.88 in 2018 Q2. Its up 0.22, from 0.66 in 2018Q1. It is positive, as 48 investors sold Baxter International Inc. shares while 321 reduced holdings. 95 funds opened positions while 230 raised stakes. 430.86 million shares or 0.30% less from 432.17 million shares in 2018Q1 were reported.

Cleararc Capital Inc has invested 0.14% of its portfolio in Baxter International Inc. (NYSE:BAX). Dakota Wealth Mngmt reported 0.14% stake. Douglass Winthrop Advsr has 0.02% invested in Baxter International Inc. (NYSE:BAX) for 6,100 shares. Peoples Services reported 0.54% of its portfolio in Baxter International Inc. (NYSE:BAX). Burt Wealth Advsr stated it has 0.01% of its portfolio in Baxter International Inc. (NYSE:BAX). Finemark Natl Bank & Tru owns 13,239 shares. Chem Natl Bank holds 0.13% or 16,842 shares in its portfolio. Moneta Gp Inv Limited Liability Corporation stated it has 0.13% in Baxter International Inc. (NYSE:BAX). Jarislowsky Fraser Ltd reported 6,678 shares stake. 564,625 were reported by Everett Harris & Ca. 4,590 are held by Btim Corp. Guardian Life Ins Of America has 1,363 shares. Paloma Partners Mgmt has invested 0.02% in Baxter International Inc. (NYSE:BAX). Pinnacle Fincl Prtnrs holds 0% or 240 shares. Tuttle Tactical Management stated it has 3,405 shares or 0.17% of all its holdings.

Since May 15, 2018, it had 0 buys, and 8 insider sales for $16.14 million activity. Pleau Scott also sold $801,450 worth of Baxter International Inc. (NYSE:BAX) on Tuesday, July 10. $1.36M worth of Baxter International Inc. (NYSE:BAX) was sold by Accogli Giuseppe on Monday, September 17. 6,594 shares were sold by Shapazian Carole J, worth $473,383. Mason Jeanne K sold $2.26 million worth of stock or 31,395 shares.

Baxter International (NYSE:BAX) Rating Reaffirmed

RBC Capital now has a $70 target on the $34.12B market cap company or 9.60 % upside potential. In an analyst report sent to clients and investors on 8 November, Baxter International (NYSE:BAX) shares have had their Sector Perform Rating restate by stock research analysts at RBC Capital.

Baxter International Inc. (NYSE:BAX) Ratings Coverage

Among 12 analysts covering Baxter International (NYSE:BAX), 9 have Buy rating, 2 Sell and 1 Hold. Therefore 75% are positive. Baxter International has $85 highest and $66 lowest target. $76’s average target is 18.99% above currents $63.87 stock price. Baxter International had 14 analyst reports since May 14, 2018 according to SRatingsIntel. Piper Jaffray initiated Baxter International Inc. (NYSE:BAX) rating on Thursday, May 17. Piper Jaffray has “Buy” rating and $7700 target. Argus Research upgraded Baxter International Inc. (NYSE:BAX) on Friday, November 2 to “Buy” rating. On Thursday, November 1 the stock rating was maintained by Leerink Swann with “Outperform”. Morgan Stanley maintained the stock with “Underweight” rating in Monday, November 5 report. The firm earned “Overweight” rating on Friday, July 27 by PiperJaffray. The company was maintained on Tuesday, May 22 by Bank of America. The rating was maintained by Wells Fargo with “Outperform” on Thursday, November 1. BMO Capital Markets maintained the shares of BAX in report on Thursday, November 1 with “Outperform” rating. The stock of Baxter International Inc. (NYSE:BAX) earned “Overweight” rating by JP Morgan on Friday, July 27. The firm has “Underweight” rating by Morgan Stanley given on Thursday, October 11.

The stock increased 0.58% or $0.37 during the last trading session, reaching $63.87. About 3.23 million shares traded. Baxter International Inc. (NYSE:BAX) has risen 18.60% since November 9, 2017 and is uptrending. It has outperformed by 2.98% the S&P500.

Baxter International Inc. provides a portfolio of renal and hospital products. The company has market cap of $34.12 billion. The firm operates through two divisions, Hospital Products and Renal. It has a 38.9 P/E ratio. The Hospital Products segment makes intravenous solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products.

Another recent and important Baxter International Inc. (NYSE:BAX) news was published by Seekingalpha.com which published an article titled: “Baxter International (BAX) Q3 2018 Results – Earnings Call Transcript” on October 31, 2018.

Baxter International Inc. (NYSE:BAX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.